Molecular Assemblies is a technology company.
Molecular Assemblies has raised $38.0M across 2 funding rounds.
Molecular Assemblies has raised $38.0M in total across 2 funding rounds.
Molecular Assemblies has raised $38.0M in total across 2 funding rounds.
Molecular Assemblies's investors include iSelect Fund.
Molecular Assemblies is a San Diego-based life sciences company founded in 2013 that develops Fully Enzymatic Synthesis (FES™) technology for producing long, high-purity DNA oligonucleotides using a template-free polymerase like terminal deoxynucleotidyl transferase (TdT).[1][2][5] This addresses limitations of chemical synthesis by enabling strands up to 400 bases long at 99.9% step-wise efficiency, serving synthetic biology, therapeutics, vaccines, immunotherapy, agriculture, nanotechnology, gene editing, gene assembly, and molecular cloning.[1][2][3][4] The company operates as a service provider, offering fast turnaround without post-synthesis purification, targeting researchers needing reliable, sequence-specific DNA for industrial synthetic biology, precision medicine, and emerging data storage applications.[2][5]
Growth momentum includes a $25.8 million Series B in March 2022 led by Casdin Capital, partnerships like the 2022 Codexis commercial license for evolved TdT enzymes, and plans for a customer program by late 2022, positioning it to scale enzymatic DNA production amid rising demand for longer oligos.[1][5]
Molecular Assemblies was co-founded in 2013 by J. William Efcavitch and Matthew Becker, experts in DNA synthesis who sought to overcome chemical methods' limits on length, purity, and accuracy by mimicking nature's enzymatic process in water.[1][5] The idea emerged from their recognition that template-independent polymerases like TdT could produce longer DNA with fewer errors, leading to a patented two-step FES™ workflow using non-toxic reagents.[1][5]
Early traction built through in-house R&D in organic chemistry, biochemistry, and protein engineering, bolstered by collaborations such as Codexis' CodeEvolver platform for enzyme optimization and investors including Agilent Technologies, Life Capital, Casdin Capital, and Alexandria Venture Investments.[1][5] Key pivots included the 2022 Series B funding to accelerate commercialization and the Codexis enzyme supply agreement, enabling a shift toward service-based delivery and a Key Customer Program.[1][5]
Molecular Assemblies rides the synthetic biology boom, where demand for long, error-free DNA fuels gene editing (e.g., CRISPR), personalized therapeutics, vaccines, agriculture, and nanotechnology amid limitations of chemical synthesis.[1][2][3][4] Timing aligns with post-2020 surges in mRNA tech and synbio investments, as longer oligos enable complex assemblies for industrial biotech and data storage, reducing error rates and costs.[2][5]
Market forces like rising oligo needs in precision medicine and sustainability pressures favor enzymatic methods, which are greener and scalable.[2][4] The company influences the ecosystem by powering next-gen products, partnering with firms like Codexis and TriLink, and enabling faster R&D cycles for startups in synbio and nanotech.[1][2][3]
Molecular Assemblies is poised to disrupt DNA synthesis as a service leader, with commercialization via customer programs and potential expansions into manufacturing scale-up.[1][5] Trends like AI-driven protein engineering, synbio therapeutics growth, and DNA data storage will amplify FES™ adoption, especially as chemical methods hit limits.[2][4] Influence may evolve through acquisitions (e.g., past Maravai interest) or broader licensing, solidifying enzymatic tech as the standard for long-DNA needs—echoing its origins in revolutionizing what nature intended.[1][2][5]
Molecular Assemblies has raised $38.0M across 2 funding rounds. Most recently, it raised $26.0M Series B in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $26.0M Series B | iSelect Fund | |
| Sep 1, 2019 | $12.0M Series A | iSelect Fund |